Last $25.68 USD
Change Today -0.33 / -1.27%
Volume 124.7K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $29.73
52 Week Low
04/24/14 - $19.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia Respiratory Syncytial Virus (RSV) and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

610 Employees
Last Reported Date: 02/24/15
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $509.1K
Chief Financial Officer
Total Annual Compensation: $313.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $307.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Business Development...
Total Annual Compensation: $329.0K
Compensation as of Fiscal Year 2013.

quidel corp (QDEL) Key Developments

Quidel Corp. Approves Amendments to the Bylaws

On February 24, 2015, the board of directors of Quidel Corporation amended and restated the company's bylaws to add as a new Article VII a forum selection provision identifying Delaware as the exclusive forum for the adjudication of certain intra-corporate disputes. The adoption of the forum selection provision is effective as of February 24, 2015.

Quidel Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Quidel Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's total revenues were USD 63,597,000 compared to USD 50,170,000 a year ago. Operating income was USD 12,915,000 compared to USD 236,000 a year ago. Income before taxes was USD 12,095,000 compared to loss before taxes of USD 89,000 a year ago. Net income was USD 7,113,000 or USD 0.20 per diluted share compared to USD 1,139,000 or USD 0.03 per diluted share a year ago. Adjusted net income was USD 13,336,000 or USD 0.37 per diluted share compared to USD 6,963,000 or USD 0.20 per diluted share a year ago. The increase in Revenue was due to greater sales of Infectious Disease products in the fourth quarter of 2014. For the year, the company's total revenues were USD 182,615,000 compared to USD 175,410,000 a year ago. Operating loss was USD 9,208,000 compared to operating income of USD 4,842,000 a year ago. Loss before taxes was USD 10,983,000 compared to income before taxes of USD 3,434,000 a year ago. Net loss was USD 7,074,000 or USD 0.21 per diluted share compared to net income of USD 7,390,000 or USD 0.21 per basic and diluted share a year ago. Adjusted net income was USD 12,342,000 or USD 0.35 per diluted share compared to USD 21,348,000 or USD 0.61 per diluted share a year ago.

Quidel Corp. to Report Q4, 2014 Results on Feb 11, 2015

Quidel Corp. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Feb 11, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $25.68 USD -0.33

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $86.66 USD +0.25
Ion Beam Applications €19.11 EUR +0.455
Luminex Corp $15.74 USD -0.23
Meridian Bioscience Inc $19.80 USD -0.01
OraSure Technologies Inc $7.16 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 3.6x
Price/Cash Flow 504.6x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at